Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 14/20 | 0.59 |
| ▸ | F10 | P00742 | 12/20 | 0.59 |
| ▸ | PLG | P00747 | 12/20 | 0.59 |
| ▸ | PLAU | P00749 | 12/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 12/20 | 0.59 |
| ▸ | PLAT | P00750 | 9/20 | 0.59 |
| ▸ | HPN | P05981 | 3/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.59 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.59 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.53 |
| ▸ | F7 | P08709 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429330 | 1.00 | F2 (0.59) | F2F10PLGPLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL1256806 | 0.99 | F2 (0.58) | F2F10PLGPLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL29614824 | 0.99 | F2 (0.58) | F2F10PLGPLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL29692564 | 0.99 | F2 (0.58) | F2F10PLGPLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL688900 | 0.99 | F2 (0.58) | F2F10PLGPLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL4259347 | 0.97 | F2 (0.56) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL2874094 | 0.83 | F2 (0.59) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL29493199 | 0.79 | F2 (0.70) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL2864097 | 0.77 | PLAU (0.52) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL4995709 | 0.74 | F2 (1.00) | F2F10PLGPLAUPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4158064-A1 | DEVICES AND METHODS FOR GENOMIC ANALYSIS | Dimensiongen (KY) | 2023-04-05 | — | — | EP | claimed |
| US-11299519-B2 | Host cells and methods using a repressor polypeptide and an inducible promoter for gene expression | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-12 | — | — | US | claimed |
| CN-112313495-A | Sample preparation for antimicrobial susceptibility testing | 赛录科试诊断公司 | 2021-02-02 | — | — | CN | claimed |
| EP-3759461-A1 | SAMPLE PREPARATION FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING | Selux Diagnostics, Inc. (US) | 2021-01-06 | — | — | EP | claimed |
| US-20200262875-A1 | Host cells and methods using a repressor polypeptide and an inducible promoter for gene expression | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-08-20 | — | — | US | claimed |
| EP-3380840-B1 | METHODS OF PREDICTING PROGRESSION OF BARRETT'S ESOPHAGUS | CERNOSTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| US-20150185150-A1 | METHOD FOR NORMALIZING THE LUMINESCENCE EMITTED BY A MEASURING MEDIUM | CISBIO BIOASSAYS (FR) | 2015-07-02 | — | — | US | claimed |
| EP-2817614-A1 | METHOD FOR NORMALISING THE LUMINESCENCE EMITTED BY A MEASURING MEDIUM | Cisbio Bioassays (FR) | 2014-12-31 | — | — | EP | claimed |
| WO-2013124544-A1 | METHOD FOR NORMALISING THE LUMINESCENCE EMITTED BY A MEASURING MEDIUM | CISBIO BIOASSAYS (FR) | 2013-08-29 | — | — | WO | claimed |
| US-7683170-B2 | Methods for preparing Irinotecan | W. C. HERAEUS GMBH (DE) | 2010-03-23 | — | — | US | claimed |
| WO-2009058997-A2 | NON-INVASIVE ISOLATION OF FETAL NUCLEIC ACID | BIOCEPT INC. (US) | 2009-05-07 | — | — | WO | claimed |
| EP-0443823-B1 | Quantitative determination of a DNA polymerase and a test kit useful in same | JOHNSON & JOHNSON CLIN DIAG (US) | 1995-11-08 | — | — | EP | claimed |
| US-5049490-A | Quantitative determination of a DNA polymerase and a test kit useful in same | EASTMAN KODAK CO. (US) | 1991-09-17 | — | — | US | claimed |
| EP-0443823-A1 | Quantitative determination of a DNA polymerase and a test kit useful in same | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1991-08-28 | — | — | EP | claimed |
| US-20260130659-A1 | EXTRACELLULAR MATRIX (ECM) HYDROGEL AS A SUBMUCOSAL FLUID CUSHION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622896-B2 | Antiviral compounds, compositions and methods of use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-12 | — | — | US | disclosed |
| US-20260125678-A1 | DNA IMMORTALIZATION CONSTRUCT AND PERFORMING PRIMARY CELL IMMORTALIZATION | GOVERNMENT OF THE US SECRETARY OF COMMERCE (US) | 2026-05-07 | — | — | US | disclosed |
| US-5049490-A | Quantitative determination of a DNA polymerase and a test kit useful in same | EASTMAN KODAK CO. (US) | 1991-09-17 | — | — | US | disclosed |
| EP-0443823-A1 | Quantitative determination of a DNA polymerase and a test kit useful in same | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1991-08-28 | — | — | EP | disclosed |
| EP-0289908-A2 | Microorganisms and methods for degrading plant cell walls and complex hydrocarbons | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125678-A1 | DNA IMMORTALIZATION CONSTRUCT AND PERFORMING PRIMARY CELL IMMORTALIZATION | MYC, TERT, POT1 | F2 2563/4885F10 2132/4885PLG 3609/4885 |
| US-20260130659-A1 | EXTRACELLULAR MATRIX (ECM) HYDROGEL AS A SUBMUCOSAL FLUID CUSHION | MMP1, SERPINE1, ADAMTS5 | F2 626/4885F10 1272/4885PLG 43/4885 |
| US-12622896-B2 | Antiviral compounds, compositions and methods of use | SARS1, NSUN2, ZC3HAV1 | F2 2900/4885F10 3888/4885PLG 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.